TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Biofrontera Inc.
Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities

Biofrontera completed its Phase 1 pharmacokinetic study for Ameluz® to expand treatment of actinic keratoses to neck, trunk, and extremities, with plans to submit a supplemental New Drug Application to the FDA in summer 2026.

Insights
SLB   neutral

Mentioned as Rockwell's joint venture partner in Sensia, with mutual agreement to dissolve the venture


BFRI   positive

Company achieved a key clinical milestone, completed a Phase 1 study, and is progressing towards expanding product usage and potential FDA approval